



Commercialising next generation drugs and diagnostics with a focus on major markets

Mr. Nicholas Weston

Chairman and Chief Executive Officer

China Bio Partnering Forum

May 2012



Agenda today

- Who we are
- A history of success
- **ThromboView®** – A revolutionary new diagnostic set for partnering / Phase III
- **Hepatitis B** – A major opportunity to develop a proven compound for China
- Reducing the risk and increasing our chances of success
- Our focus is to create long term value



Agenix snapshot

Corporate	AGENIX specialises in advanced medical diagnosis of human diseases. We are positioned as a world-class thrombosis and blood clot specialist and leading anti-viral developer for China.
Objective	Create long term shareholder value by rapidly commercialising next generation drugs and diagnostics with a focus on major market s in the US and China
Lead products	ThromboView® Revolutionary new diagnostic blood clot imaging agent Successfully completed two FDA Phase II trials Currently in partnering / licensing discussions AGX-1009 NtARTI prodrug of tenofovir for chronic hepatitis B Pre-clinical trials in progress
Leadership	Commercial board and management with proven ability to deliver outcomes
Listing	ASX: AGX (1987)
Locations	Melbourne Australia and Shanghai China
Cash	A\$0.6 million @31 December 2011
Value Inflection points	Partnering / Licensing of ThromboView® AGX 1009 State Food & Drug Administration CTA filing
Structure	766,375,347 shares outstanding, 7,991,307 options outstanding, Mkt cap ~A\$5m

Commercially focused management




- **Nicholas Weston**
Group Chairman & CEO




- **Mike Gerometta Ph.D.**
Chief Science Officer –
ThromboView®

- Our people are Agenix's core assets and strengths
- Proven technical and China skills of directors, management and team are driving our business forward to create long term shareholder value.



A history of creating value

Since 1987 Agenix has taken ~ 20 animal and human products across 4 technology platforms to successful commercialisation and/or strategic sale and exit



Recent accomplishments

Technical

ThromboView® clot imaging agent

- peer reviewed publications in:
 - – *Heart Lung and Circulation*
 - – *American Journal of Respiratory and Critical Care Medicine*

AGX-1009
(tenofovir prodrug)
demonstrated
manufacturing in
pre-clinical batches
to 99.63% purity

Pre-clinical

AGX-1009 toxicology contracts signed

- with Institute of Pharmacology and Toxicology of the Chinese Academy of Military Medicine Sciences

Commercial

AGX-1009

- compound patent transferred to Agenix from IMB
- PCT manufacturing patent filed

ThromboView®

- potential licensing partners are conducting due diligence

Strategy to create long term value

Complete transformation to a company based on capital:

human capital
(experience, creativity,
networks, core
competencies)

relationship capital (ASX
listed since 1987,
partners, consultants,
suppliers, customers,
hospitals, universities,
alumni, scientific
advisory board, goodwill)

intellectual capital
(patents, copyright, trade
marks, licensing)

organisational capital
(research
methodologies,
reference material,
research results)

monetary capital
(raisings, recoveries)

Partnering our capital with:

China infrastructure and
technical skills

Driving business by:

reference to technical,
clinical and commercial
value inflection points
and realistic milestones

Competent execution
of basics:

Good corporate
governance
Mitigating risk


Communicating
milestones and results.

Prudent use of capital

A business with multiple opportunities

ThromboView® diagnostic

- Uniquely, images blood clots based on molecular structure
- Radiolabelled Fab' fragment of humanised 3B6 epitope binds to clots then SPECT
- 3B6 epitope has >250 referenced publications since 1982



Hepatitis B anti-viral drug

- Proprietary AGX-1009 compound is a tenofovir prodrug with the same active compound as Gilead's FDA-approved Viread but with a different 'sidechain'
- As a prodrug of a marketed product, AGX-1009 has relatively low risk compared to a new chemical entity

China's State Intellectual Property Office (SIPO) approved the patent application of AGX-1009 after it authorized five tenofovir related patents to Gilead, which indicates that Gilead's patents have little impact on AGX-1009 at compound level.



ThromboView[®] is safe and effective

Safety

“There were no treatment-related serious adverse events.”


- *Morris et al.* Detection of pulmonary emboli with 99mTc-labeled anti-d-dimer (di-80b3)fab' fragments (thromboview). *American Journal of Respiratory and Critical Care Medicine* 2011;in press

Effectiveness

“Binds in situ to clots of almost any size and location. Binds only to defects that represent clots, not vascular scars. No clot, no anti-clot Rx. Binds despite anticoagulation.”

Professor Tim Morris, UCSD March 2011


- **Relatively low radiation exposure**
- **Avoids exposure to nephrotoxic contrast dye**
- **Sensitivity and specificity comparable to CTPA**





ThromboView[®] has many advantages

**CXR
equivalents**



2- 4 CXR equivalents vs. 100- 400 for current standard CT scans (breast/chest dose)
Less exposure to radiation

**Contrast
induced
nephropathy**



No contrast induced nephropathy as opposed to current CT scans, which has 10-11%
Use in patients with contra-indications to toxic contrast dye

**Identified
old vs. new
blood clots**




Unlike current standard CT scans, ThromboView detects and differentiates *newly* formed blood clots vs. existing ones
Early detection of risk of recurrence and may reduce long-term use of anti-coagulants


ThromboView[®] answers clinical demand



Incidence of VTE in the US
Thousands



Unmet needs



Full market potential remains untapped



Issues	CT Scan	Thrombo-View	ThromboView addresses unmet need
Poor timing of contrast dye administration with CT scan can produce inconclusive images, necessitating repeat testing. This increases breast radiation exposure	✗	✓	ThromboView is an antibody-radioisotope conjugate which eliminates timing issues of CT with contrast dye. Images are taken after a delay period and are not time-sensitive. Radiation dose to the breast region is low
Patient with idiopathic DVT or recurrent DVT are generally treated with anticoagulation for a life time – due to inconclusive diagnosis	✗	✓	ThromboView can differentiate newly formed clots from old clots and may help clinicians determine the risk benefit profile for appropriate anticoagulation therapy
Clinicians are looking for a diagnostic tool to differentiate chronic vs. recurrent clots	✗	✓	
Decreasing occurrence of nephrotoxicities	✗	✓	ThromboView avoids nephrotoxicity associated with intravenous contrast dye and is the alternative to evaluate thrombosis in patients who have contraindications to the contrast dye



ThromboView® on track to create value

Strategic transaction discussions underway

- ongoing with several groups in multiple geographies

The strategic transaction objective is to:

- partner fully funded ThromboView® Phase III trials

We anticipate our discussions will continue:


- into 2H 2012
- our focus is long term shareholder value




AGX-1009 – A low risk proven compound

AGX-1009 is a next-generation Nucleotide analog reverse-transcriptase inhibitor (NtARTIs or NtRTI) patented tenofovir ‘prodrug’ with the **same active compound** as Gilead’s FDA-approved Viread but activated by a different molecular sidechain.

Tenofovir (Viread) is FDA approved in USA for HIV and HBV. **It is not approved in China.**



AGX-1009 – Meets major medical needs





Value inflection points – near term

ThromboView®

- Potential partners currently conducting due diligence including access to technology fees, milestone payments, royalties
- Potential Phase III start
- Progress of patent applications in key markets (China, Canada)
- Additional peer publications

AGX-1009

- Data available from pre-clinical studies of tenofovir prodrug AGX-1009
- Announcements regarding proof of confidence
- SFDA CTA filing expected 2H 2012
- Announcements regarding distribution and clinical partnerships
- Potential licensing deals in key geographies
- Potential clinical trial approval in 2013
- Potential commencement of combination trials
- Progress of patent applications

Pipeline

- Technical, clinical and commercial opportunities to build a late stage pipeline or assets that are accretive in the near term.



Agenix – Summary

- Growth powered by next generation therapeutics and diagnostics
- Meeting large unmet medical needs with innovative new products that transform the way common diseases are treated
- Opportunity to improve quality of life for millions of people
- A milestone driven and outcomes focused business
- A focused approach to reducing risk and creating long term shareholder value and create a world class company
- Commercially focused management team and board with a proven ability to deliver shareholder value
- Actively seeking to grow our pipeline and welcome partners.



Thank you

www.agenix.com





Addendum



Solid intellectual property estate

ThromboView® blood clot diagnostic

- Patents registered in Japan, USA, EU, Singapore, Australia, New Zealand to 2022 with possible Hatch-Waxman extension to 2027
- Patent application under examination in China, Canada
- Data protection as a biologic 10 years EU and 12 years USA from date of regulatory approval

AGX-1009 anti hepatitis B compound

- Patent registered in China for AGX-1009 small molecule compound after Gilead patents indicating third party patents will have little impact on AGX-1009 molecule protection
- PCT applications for synthesis methods



Risk balanced strategic approach

Issue	Strategy and approach
Clinical results	• ThromboView® successfully completed Phase I and Phase II • AGX-1009 based on a proven existing active compound • Significantly lower risk profile to a new drug compound
Timing & delivery	• Working with strategic partners who are the experts in China • Minimum errors in data and regulatory submissions in China • Government priority to support new drugs like AGX-1009
Intellectual property	• ThromboView® protected by broad patents until at least 2022 • Continue to build and will aggressively defend • AGX-1009 protected by manufacturing patent applications in key global markets and compound is patented in China
Capital needs	• Continue to develop strong supportive shareholder base • Close control of costs and programs to reduce our burn rate
Sentiment	• Communicating our progress clearly and effectively • Proven strategic partners in China • Positioned to meet major unmet medical needs in China • Well managed company with strong management team



Effective working partnerships

Our partners include experienced State Food and Drug Administration (SFDA) hands and Hepatitis B experts

Acquisition of AGX-1009 patents:

Institute of Medicinal Biotechnology (IMB), Chinese Academy of Medical Sciences (CAMS), Beijing

Pre-clinical partners:

Institute of Pharmacology and Toxicology (IPT), Chinese Academy of Military Medical Sciences (AMMS), Beijing

Drug manufacturing partner:

Beijing Honghui Meditech

Clinical trials, ThromboView®:

University of California, San Diego, USA



ThromboView[®] - Ready for Phase III

Study	Subjects	Design	Objectives
Phase Ia	32, healthy volunteers	Single center, 4 ascending doses	To test safety, pharmacokinetic and dosimetry profile
Phase Ib	26 patients diagnosed with DVT	Multi-center, 3 ascending doses	To test safety, pharmacokinetic and dosimetry profile in patients
Phase Ib	15 patients diagnosed with PE by CTPA	Multi-center, single dose (0.5mg)	To assess safety and tolerability Proof of concept
Phase II	82 patients with confirmed DVT by venography	11 sites in the US and Canada, single dose	To assess sensitivity and specificity
Phase II	52 patients with high to moderate probability of PE	7 sites in the US and Canada, single dose	To assess sensitivity and specificity




ThromboView[®] has multiple applications

	Research	Pre-clinical	Phase 1	Phase 2	Phase 3	Regis- tration	Market
99m Tc – hu3B6							
DVT Dx							
PE Dx							
Recurrent DVT							
Arterial/AF							
Monitor Therapy/ Rpt Dose							
ICU Setting							
hu3B6 + alternative tag							
PET (ANSTO)							
MRI/US							


ThromboView[®] – pharmacokinetics

- A large and growing body of independent clinical evidence confirms ThromboView[®] is safe and well tolerated in a range of patients




Hepatitis B (HBV) market in China

- Major unmet medical problem
- Significant cost to medical system
- Burden to millions of Chinese
- Government priority to address
- US\$1.3 billion market in 2019



Sales of Hepatitis B drugs in China

(Million, RMB)



SOURCE: IMS HEALTH